GLPwatch
The Effect of Semaglutide on the Intestinal Flora in Obesity
NCT07323134 · Not yet recruiting
Last updated 2026-05-28This clinical trial is testing how the medication semaglutide affects gut bacteria in adults with obesity.
Status Not yet recruiting Approved but enrollment has not started.
Type Observational
Participants 40 people Planned (estimated).
Who can join Ages 18–60 · all sexes
Timeline Started 2026-02 · est. completion 2026-08
What this study is testing ClinicalTrials.gov NCT07323134 ↗
Description as written by the study sponsor.
For obese individuals, semaglutide treatment was adopted. By using multi-omics techniques such as fecal metagenomic sequencing and based on in vitro strain screening platforms, the effects and specific mechanisms of semaglutide on the intestinal flora of obese patients were clarified.
Treatments tested
- Semaglutide Injection Drug
Semaglutide Injection
| Main thing measured | The composition of the gut microbiota changes relative to the baseline |
|---|---|
| Sponsor | Beijing Chao Yang Hospital |
| Conditions studied | Obesity |
| GLP-1 drugs | semaglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07323134 ↗